NASDAQ:CAPR Capricor Therapeutics (CAPR) Stock Price, News & Analysis $20.61 -0.90 (-4.18%) Closing price 07/13/2026 04:00 PM EasternExtended Trading$20.42 -0.20 (-0.95%) As of 07:30 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Capricor Therapeutics Stock (NASDAQ:CAPR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Capricor Therapeutics alerts:Sign Up Key Stats Today's Range$20.17▼$21.5350-Day Range$20.61▼$34.3852-Week Range$4.30▼$40.37Volume1.27 million shsAverage Volume1.60 million shsMarket Capitalization$1.19 billionP/E RatioN/ADividend YieldN/APrice Target$53.67Consensus RatingModerate Buy Company Overview Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms. The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury. Capricor has completed a Phase II trial in DMD that demonstrated potential functional benefits in ambulatory and non-ambulatory patients, and it has initiated follow-on studies to further characterize safety and efficacy. In addition, Capricor’s CAP-2003 program harnesses exosomes derived from CDCs to deliver bioactive molecules that may promote tissue repair, representing a next-generation approach to regenerative medicine. Capricor serves patients throughout the United States and collaborates with academic and clinical research institutions to accelerate the translation of its therapies. The company’s research and development efforts are supported by strategic partnerships that provide access to specialized manufacturing, preclinical models, and clinical trial networks. Capricor’s leadership team is led by President and CEO Linda L. Marbán, PhD, who co-founded the company and has overseen its growth from an early-stage venture to a publicly traded biotech enterprise.AI Generated. May Contain Errors. Read More Capricor Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks51st Percentile Overall ScoreCAPR MarketRank™: Capricor Therapeutics scored higher than 51% of companies evaluated by MarketBeat, and ranked 518th out of 852 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingCapricor Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 1 strong buy rating, 8 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialCapricor Therapeutics has a consensus price target of $53.67, representing about 160.4% upside from its current price of $20.61.Amount of Analyst CoverageCapricor Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Capricor Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Capricor Therapeutics are expected to decrease in the coming year, from ($0.49) to ($0.73) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Capricor Therapeutics is -8.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Capricor Therapeutics is -8.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCapricor Therapeutics has a P/B Ratio of 3.73. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Capricor Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted28.03% of the float of Capricor Therapeutics has been sold short.Short Interest Ratio / Days to CoverCapricor Therapeutics has a short interest ratio ("days to cover") of 7.38.Change versus previous monthShort interest in Capricor Therapeutics has recently increased by 25.97%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCapricor Therapeutics does not currently pay a dividend.Dividend GrowthCapricor Therapeutics does not have a long track record of dividend growth. News and Social Media2.9 / 5News Sentiment0.63 News SentimentCapricor Therapeutics has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.87 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Capricor Therapeutics this week, compared to 9 articles on an average week.Search Interest9 people have searched for CAPR on MarketBeat in the last 30 days. This is an increase of 29% compared to the previous 30 days.MarketBeat Follows9 people have added Capricor Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership1.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Capricor Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,551,658.00 in company stock.Percentage Held by Insiders9.20% of the stock of Capricor Therapeutics is held by insiders.Percentage Held by Institutions21.68% of the stock of Capricor Therapeutics is held by institutions.Read more about Capricor Therapeutics' insider trading history. Receive CAPR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Capricor Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CAPR Stock News HeadlinesCapricor Therapeutics (CAPR) Gets a Buy from Cantor FitzgeraldJuly 8, 2026 | theglobeandmail.comCapricor Therapeutics Insider Trading Activity | NASDAQ:CAPR | BenzingaJuly 5, 2026 | benzinga.comMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon adviser Jim Rickards publicly predicted a Trump victory before election night. Now Rickards is issuing a new forecast he calls a potential mid-term meltdown, one he believes could send shockwaves through financial markets.July 14 at 1:00 AM | Paradigm Press (Ad)Capricor Therapeutics (NASDAQ:CAPR) CFO Anthony Bergmann Sells 24,100 SharesJuly 1, 2026 | insidertrades.comCAPR stock hits over 4-month low: Capricor execs cash in $1.5M as FDA sets stage for DMD drug reviewJune 30, 2026 | msn.comWhat's going on with Capricor Therapeutics stock on Friday?June 26, 2026 | msn.comCapricor falls as FDA sets up AdCom meeting to review Duchenne therapyJune 26, 2026 | seekingalpha.comAnthony Bergmann Sells 400 Shares of Capricor Therapeutics (NASDAQ:CAPR) StockJune 25, 2026 | insidertrades.comSee More Headlines CAPR Stock Analysis - Frequently Asked Questions How have CAPR shares performed this year? Capricor Therapeutics' stock was trading at $28.86 at the beginning of the year. Since then, CAPR shares have decreased by 28.6% and is now trading at $20.61. How were Capricor Therapeutics' earnings last quarter? Capricor Therapeutics, Inc. (NASDAQ:CAPR) announced its earnings results on Tuesday, May, 12th. The biotechnology company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.55) by $0.04. Read the conference call transcript. How do I buy shares of Capricor Therapeutics? Shares of CAPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Capricor Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Capricor Therapeutics investors own include Advanced Micro Devices (AMD), Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Moderna (MRNA), Netflix (NFLX) and Alphabet (GOOG). Company Calendar Last Earnings5/12/2026Today7/14/2026Next Earnings (Estimated)8/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (7m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 CAPR's financial health is in the Green zone, according to TradeSmith. CAPR has been in this zone for over 7 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED PRODUCTS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CAPR CIK1133869 Webwww.capricor.com Phone310-358-3200Fax415-875-7075Employees101Year Founded2005Price Target and Rating Average Price Target for Capricor Therapeutics$53.67 High Price Target$63.00 Low Price Target$38.00 Potential Upside/Downside+160.4%Consensus RatingModerate Buy Rating Score (0-4)2.90 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($2.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$105.04 million Net MarginsN/A Pretax MarginN/A Return on Equity-59.27% Return on Assets-48.65% Debt Debt-to-Equity RatioN/A Current Ratio8.42 Quick Ratio8.42 Sales & Book Value Annual Sales$22.27 million Price / Sales53.59 Cash FlowN/A Price / Cash FlowN/A Book Value$5.53 per share Price / Book3.73Miscellaneous Outstanding Shares57,910,000Free Float52,584,000Market Cap$1.19 billion OptionableOptionable Beta0.42 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Get This Free Report This page (NASDAQ:CAPR) was last updated on 7/14/2026 by MarketBeat.com Staff. From Our PartnersTrump’s $250 Bill – See ImmediatelyFormer Goldman Sachs VP Dr. David Eifrig is warning that July 28 could trigger the biggest wealth reset in mod...Stansberry Research | SponsoredSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredThey told you not to miss this oneThe largest companies in the SP 500 are now more overvalued relative to fundamentals than they were at the abs...Thor Metals | SponsoredForget SpaceX, this is Elon’s Next BreakthroughJeff Brown and Marc Chaikin - two investors who called Nvidia a decade ago - say Elon Musk's newly filed AI pa...Brownstone Research | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe spice must flowChina controls 98% of global gallium production and the vast majority of refined rare-earth output - the mater...Porter & Company | SponsoredThe $5 company SpaceX can’t survive withoutThe investors who got rich on AI didn't all buy Nvidia. Some bought ASML, the company that makes the machines ...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Capricor Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Capricor Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
